血液透析患者接受[177Lu]Lu-PSMA治疗的剂量学病例研究
本病例研究报告一名合并肾衰竭的转移性去势抵抗性前列腺癌患者接受五个周期[177Lu]Lu-PSMA-I&T治疗的剂量学监测经验。通过影像、血液和透析液采样评估危险器官辐射剂量及透析期间活度分布,结果显示各器官剂量低于安全阈值,骨髓剂量虽较文献升高约两倍但未出现严重血液毒性。
要点
- 透析患者接受[177Lu]Lu-PSMA治疗时骨髓剂量较文献升高约两倍但仍低于严重确定性效应阈值。
- 血液透析期间血中活度浓度3小时内下降32%,透析结束后出现活度回弹。
- 需对首次透析采取辐射防护措施,本病例在给药后20小时于放射性配体治疗护理单元进行。
核心结论
- 合并肾衰竭的血液透析患者接受[177Lu]Lu-PSMA治疗时,经仔细监测的辐射剂量仍低于安全剂量阈值,且未观察到严重血液毒性征象。
研究设计与样本
- 单例病例研究,72岁转移性去势抵抗性前列腺癌合并肾衰竭患者接受共五个周期约7.4 GBq [177Lu]Lu-PSMA-I&T治疗,每周期间隔5–7周。
- 通过影像、血液采样和透析液采样监测危险器官辐射剂量及血液透析期间活度分布。
主要发现
- 每周期辐射剂量(均值±标准差):全身0.51±0.06 Gy,肝脏(含肿瘤)5.6±0.5 Gy,单侧肾功能不良肾脏3.3±0.4 Gy,唾液腺5.5±0.7 Gy,骨髓0.41±0.07 Gy。
- 血液透析每周继续三次;透析期间血中活度浓度3小时内下降32%,透析结束后出现活度回弹。
- 该透析患者骨髓辐射剂量较文献升高约两倍,但仍低于严重确定性副作用的剂量阈值。
关键数值与推荐
- 每周期给药活度约7.4 GBq [177Lu]Lu-PSMA-I&T,共五个周期,周期间隔5–7周。
- 首次血液透析在给药后20小时进行,于放射性配体治疗护理单元采取辐射防护措施。
临床怎么用
- 对合并肾衰竭的透析患者行[177Lu]Lu-PSMA治疗时,应仔细监测危险器官辐射剂量及透析期间活度分布。
- 首次透析需采取辐射防护措施,并关注透析后活度回弹现象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this case study, we share our experience on the treatment of a patient with [177Lu]Lu-PSMA for metastatic castration-resistant prostate cancer and comorbid kidney failure. Since a poor kidney function impacts [177Lu]Lu-PSMA clearance, the aim of this study was to carefully monitor the radiation dose to the organs-at-risk, and measure the activity distribution during hemodialysis sessions, by imaging, blood sampling and dialysate sampling. CASE PRESENTATION: A 72-year-old patient received a total of five cycles of approximately 7.4 GBq [177Lu]Lu-PSMA-I&T, with an interval of 5–7 weeks per cycle. The radiation dose per cycle (mean ± SD) was measured for different regions: total body 0.51 ± 0.06 Gy, liver (incl. tumours) 5.6 ± 0.5 Gy, kidney (single, poor function) 3.3 ± 0.4 Gy, salivary glands 5.5 ± 0.7 Gy, and bone marrow 0.41 ± 0.07 Gy. Hemodialysis was continued three times a week. Precautions for radiation protection were taken for the first hemodialysis session 20 h after [177Lu]Lu-PSMA administration, which took place at the radioligand therapy nursery unit. Blood and dialysate samples, collected during hemodialysis, showed a drop of the activity concentration in the blood of the patient (32% in 3 h), and a partial return of activity to the blood (rebound effect) after the end of the hemodialysis treatment. The radiation dose to the bone marrow of the hemodialysis patient was elevated (by a factor of two as compared to literature), but stayed below dose thresholds for severe deterministic side effects. CONCLUSIONS: Despite the preexisting kidney failure of a hemodialysis patient, the carefully monitored radiation dose of [177Lu]Lu-PSMA therapy remained below safe dose thresholds and no signs of severe hematotoxicity were observed.
引用
- Hendriks AD, Abrahams AC, van Rooij R, et al. Dosimetry of [177Lu]Lu-PSMA therapy in a hemodialysis patient: a case study. EJNMMI Res. 2026. PMID: 42020659. doi:10.1186/s13550-026-01433-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。